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Introduction. Treatment of open fractures routinely involves multiple surgeries and delayed definitive fracture fixation because of
concern for infection. If implants were made less susceptible to infection, a one-stage procedure with intramedullary nailing
would be more feasible, which would reduce morbidity and improve outcomes. Methods. In this study, a novel open fracture
mouse model was developed using Staphylococcus aureus (S. aureus) and single-stage intramedullary fixation.)emodel was used
to evaluate whether implants coated with a novel “smart” polymer coating containing vancomycin or tigecycline would be
colonized by bacteria in an open fracture model infected with S. aureus. In vivo bioluminescence, ex vivo CFUs, and X-ray images
were evaluated over a 42-day postoperative period. Results. We found evidence of a markedly decreased bacterial burden with the
local release of vancomycin and tigecycline from the PEG-PPS polymer compared to polymer alone. Vancomycin was released in a
controlled fashion and maintained local drug concentrations above the minimum inhibition concentration for S. aureus for
greater than 7 days postoperatively. Bacteria were reduced 139-fold from implants containing vancomycin and undetected from
the bone and soft tissue. Tigecycline coatings led to a 5991-fold reduction in bacteria isolated from bone and soft tissue and 15-fold
reduction on the implants compared to polymer alone. Antibiotic coatings also prevented osteomyelitis and implant loosening as
observed on X-ray. Conclusion. Vancomycin and tigecycline can be encapsulated in a polymer coating and released over time to
maintain therapeutic levels during the perioperative period. Our results suggest that antibiotic coatings can be used to prevent
implant infection and osteomyelitis in the setting of open fracture. )is novel open fracture mouse model can be used as a
powerful in vivo preclinical tool to evaluate and optimize the treatment of open fractures before further studies in humans.
1. Introduction
Open fractures are often devastating injuries for patients. In
addition to challenges of fracture healing in dramatically
injured and denudated bone, exposure to the “outside
world” results in osteomyelitis in up to 50% of cases [1, 2].
Nonunion rates are reported as high as 16% in open frac-
tures (as compared to less than 5% in closed fractures), and
eventual amputation is not uncommon [3, 4]. Even with
successful treatment, patient satisfaction scores are low and
the cost to treat these infections is high [5, 6]. Annually,
there are approximately 6 million fractures in the United
States, and nearly 4% are open, suggesting an estimated
240,000 open fractures [5, 7]. )is epidemic is particularly
pronounced in the military, where contaminated extremity
fractures from blast wounds remain the most common
injury of military personnel in the battlefield with associated
infection rates reported as high as 20–30% [8–10]. )e
standard of care for open fractures includes administration
of intravenous antibiotics as soon as possible after the injury,
urgent washout, and continuation of antibiotics for a
minimum of 24 hours after wound closure [11]. Surgical
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fixation of open fractures depends on the severity and lo-
cation of the injury. While most long bone injuries are
treated with intramedullary nail fixation, periarticular or
small bone fractures are often treated with plates and screws,
and external fixation remains a viable treatment option,
especially for temporization.
Infection rates remain high despite this “best practice”
[5, 6]. )is is partially due to the formation of biofilm on the
implant surface, which prevents intravenous antibiotics and
the innate immune response from reaching bacteria [12, 13].
While one option to decrease this phenomenon is to perform
repeat irrigation and debridement procedures to clean the
fracture site prior to internal fixation, this requires multiple
surgeries, a prolonged hospital stay, and an enormous cost to
the healthcare system. Another option is to utilize external
fixation, but patient satisfaction scores are low and repeat
operation for definitive fixation is usually required [14].
)erefore, new methods must be developed to allow efficient
orthopaedic stabilization of fractures in the setting of
contaminated wounds. A one-step method of fracture fix-
ation with a device that both protects its own surface from
bacterial adhesion and releases antibiotics to improve local
clearance of infection has potential to improve patient
outcomes and conserve resources. )e concept of local
delivery of antibiotics in the setting of an open fracture is not
a new one. Antibiotic irrigation has been used for many
years in open fractures although recent literature has
questioned its effectiveness [6, 15]. Vancomycin and gen-
tamicin have been delivered locally in open fractures using
polymethyl methacrylate (PMMA) cement beads, resulting
in lower postoperative infection rates compared to in-
travenous antibiotics alone (4% versus 12%–16%) [16, 17].
However, these patients require a second operation to
remove the residual cement, and the implant surface is not
protected, leaving it susceptible to bacterial seeding and
biofilm formation. Newer biodegradable antibiotic beads
have been developed, eliminating the need for a second
operation, but they also do not protect the implant from
bacterial seeding or elute antibiotics into the intramedullary
canal to prevent ascending or descending osteomyelitis.
Antibiotic cement has also been used to coat intramedullary
implants [18]. Drawbacks of this technique include limited
control of elution properties, long-term retention of a
nonantimicrobial coating once the antibiotics have eluted,
and the inability to coat plates and screws. Our objective in
this study was to develop a bioabsorbable implant coating to
deliver antibiotics locally via an intramedullary implant.
Additionally, the polymer coating was designed to confer
several specific unique benefits: (1) the coating polymerizes
rapidly in a nonexothermic reaction, allowing incorporation
of heat sensitive antibiotics and antimicrobials, (2) the
coating can release antibiotics over a sustained period of
time, and (3) the coating is completely biodegradable and
has been demonstrated to not have a negative effect on
osseointegration [19]. A mouse model of postarthroplasty
infection using a bioluminescent strain of Staphylococcus
aureus (S. aureus) has previously been established [20–24].
)is model has been used to understand the immune re-
sponse to such infections as well as to the evaluate the
efficacy of perioperative antibiotics and treatment of chronic
infections [22, 24]. In the present study, we adapted our
mouse model to an open fracture model by creating a defect
in the femoral diaphysis and inoculating S. aureus into the
open thigh wound, more consistent with a blast injury.
Vancomycin is commonly used in the treatment of such
open fracture infections, but it is unclear if it is the optimal
antibiotic against S. aureus [25]. Tigecycline is a newer
antibiotic with increased antimicrobial activity against both
MSSA and MRSA, especially against biofilm formation in
both in vitro and in vivo settings [26, 27]. )us, we in-
corporated vancomycin or tigecycline into a novel PEG-PPS
polymer covalently linked to an intramedullary implant and
evaluated the efficacy of these coatings against a local S.
aureus infection.
2. Methods
2.1. Synthesis of PEG-PPS Block Copolymer Antibiotic
Coatings. )e synthesis of the PEG-PPS polymer was the
same as previously described [19]. An orthopaedic-grade
titanium Kirschner-wire (K-wire) (diameter 0.6mm) un-
derwent oxygen plasma treatment at 200mTorr and 200W
for 15min. Subsequently, 1% (v/v) (3-mercaptopropyl)
trimethoxysilane was reacted with the K-wire in toluene at
90°C with stirring followed by sonication in chloroform (5
times), acetone (2 times), methanol (5 times), and milliQ
water (5 times). )e K-wire was then heated at 50°C for at
least 30 minutes to dry. )e PEG-PPS polymer was then
dissolved in phosphate buffer saline (PBS) to make either a
3% or 6% (w/v) solution, which was used to dissolve either
tigecycline or vancomycin at a concentration of 20mg/ml.
)e K-wires were submerged in the antibiotic-encapsulated
PEG-PPS solution or PEG-PPS solution alone at 4°C and
dried at 50°C. )is wet-dry cycle was repeated for a total of
ten times. To aid in visualization of the coating, rhodamine
was also coated on the titanium pins via encapsulation in
PEG-PPS solution. )e microstructure of the polymer
coatings was characterized using Nano SEM with X-ray
microanalysis.
2.2. In Vitro Antibiotic Release Kinetics. In vitro release of
vancomycin and tigecycline from the PEG-PPS coating on
titanium K-wires was conducted, as previously described
and validated, by submerging pins in 200 μl of PBS at 37°C.
)e amount of released vancomycin was quantified by high-
performance liquid chromatography (HPLC) based on its
UV absorption at 280 nm, and the buffer was refreshed daily
for at least one week. Known concentrations (0, 1, 5, 10, 20,
40, and 100 μg/mL) of vancomycin dissolved in PBS were
used to generate a calibration curve with HPLC under the
same method, using 0.1% trifluoroacetic acid at a flow rate of
0.1mL/min [19].
2.3. S. aureus Bioluminescent Strain. S. aureus Xen36
(PerkinElmer, Hopkinton, MA) is a bioluminescent de-
rivative of the S. aureus ATCC 49525 (Wright) strain, a
clinical isolate from a bacteremic patient that has been used
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in previous animal studies [20, 24, 28]. )is strain has a
Gram-positive optimized luxABCDE operon stably in-
tegrated into a native plasmid, and live, actively metabolizing
bacteria naturally emitting a blue-green light with a maximal
emission wavelength of approximately 490 nm (Francis
2000). )eminimum inhibition concentration for Xen36 for
vancomycin is ≤0.5 μg/ml and for tigecycline is ≤0.25 μg/ml.
S. aureus Xen36 has previously been shown to be optimal for
use due to the strength and consistency of its signal [20].
2.4. Preparation of S. aureus for Inoculation. S. aureus Xen36
possesses a kanamycin resistance selection marker, enabling
isolation from contaminating background strains during
culture. )us, 200 μg/ml kanamycin (Sigma-Aldrich, St.
Louis, MO) was added to all cultures. S. aureus Xen36 was
streaked onto tryptic soy agar plates (tryptic soy broth (TSB)
plus 1.5% bacto agar (BD Biosciences, Franklin Lakes, NJ))
and grown at 37°C overnight [20–24]. Single colonies were
cultured in TSB and grown overnight at 37°C in a shaking
incubator (240 rpm) (MaxQ 4450; )ermo, Waltham, MA).
Midlogarithmic phase bacteria were obtained after a 2 h
subculture of a 1 : 50 dilution of the overnight culture. Cells
were pelleted, resuspended, and washed 3 times in phos-
phate buffered saline (PBS). Bacterial concentrations were
estimated by measuring the absorbance at 600 nm (A600;
Biomate 3 ()ermo, Waltham, MA)). Colony-forming units
(CFUs) were verified after overnight culture of plates.
2.5. Mouse Surgical Procedures. Twelve-week-old male
C57BL/6 mice (n� 6 per group) were used in all experi-
ments. Animals were kept at 3 mice per cage in standard
cages with a 12-hour light and dark cycle. )ey were fed a
standard pellet diet with free access to bottled water. As-
sessments were carried out daily by veterinary staff to ensure
the well-being of all animals throughout the experiment.)e
surgical procedure for this open fracture model was adapted
from the surgical procedure from our previously validated
mouse model of prosthetic joint infection [20–24]. A medial
parapatellar knee arthrotomy was made and a medical-grade
titanium K-wire coated with either PEG-PPS alone, PEG-
PPS containing vancomycin, or PEG-PPS containing tige-
cycline was implanted into the femoral intramedullary canal
in a retrograde fashion. A separate incision was then made
1 cm proximal to the joint space on the lateral aspect of the
thigh and a 2mm femoral defect created at the level of the
midshaft femur. A micropipette was used to inoculate S.
aureus Xen36 (1× 108CFUs in 2 μl saline) into the surgically
created open fracture site. )e two surgical wounds were
closed using 5–0 vicryl sutures. Analgesia (2.5mg/kg sus-
tained-release buprenorphine) was administered at the time
of surgery as well as every 3 days postoperatively.
2.6. High-Resolution X-Ray Imaging. Lateral radiographs of
the femur were obtained using high-resolution X-ray
(Faxitron LX-60 DC-12 imaging system) immediately after
surgery to ensure proper placement of the implant. Images
were also taken on postoperative day (POD) 21 and POD 42.
A fellowship trained orthopaedic surgeon evaluated the
high-resolution X-ray images to determine whether van-
comycin- or tigecycline-coated implants had any impact on
bony architecture and implant stability at 3 and 6 weeks.)e
evaluator was blinded to the treatment groups and assessed
implant stability, osteolysis, and appearance of osteomyelitis
or involucrum.
2.7. Quantification of S. aureus Bacterial Burden Using Bio-
luminescence Imaging In Vivo and CFUs. Mice were anes-
thetized via inhalation of isoflurane (2%) and in vivo
bioluminescence imaging was performed by using the
Xenogen in vivo imaging system (Xenogen IVIS; Caliper Life
Sciences, WalthamMA). Images were obtained on POD 0, 3,
7, 14, 21, 28, 35, and 42 as previously described [20–24]. Data
are presented on color scale overlaid on a grayscale pho-
tograph of mice and quantified as maximum flux (photons
per second (s) per cm2 per steradian (sr) (p/s/cm2/sr)) within
a circular region of interest (1× 103 pixels) by using Living
Image software (Xenogen, Alameda, CA).
To confirm that the bioluminescence signals corresponded
to the bacterial burden in vivo, the mice were euthanized
following the last day of imaging, POD 42, and the implant and
surrounding tissue were cultured. Bacteria were detached from
the implant by sonication in 1ml 0.3% Tween-80 in TSB for 10
minutes followed by vortexing for 5 minutes as previously
described [16]. In addition, bacteria in the surrounding joint
tissue were measured by homogenizing bone and joint tissue
(Pro200H Series homogenizer; Pro Scientific, Oxford, CT).)e
number of bacterial CFUs that were adherent to the implant
and in the joint tissue was determined by counting CFUs after
overnight culture of plates and was expressed as total CFUs
harvested from the implant and joint tissue. To confirm the
absence of bacteria in samples measuring zero CFUs, ho-
mogenates were cultured in TSB for 48 hours at 37°C in a
shaking incubator and then plated overnight, and presence or
absence of CFUs was determined.
2.8. Statistical Analysis. Each group had 6 mice based on
previous bioluminescence studies from our group showing
that 6 animals/group were necessary to attain statistical
significance [16–18, 20, 21]. Data between two groups were
compared using Student’s t-test (one- or two-tailed where
indicated), while data between three or more groups were
compared using a one-way ANOVA. All data are expressed
as mean and standard error of the mean (SEM). Values of
p< 0.05 were considered statistically significant.
3. Results
3.1. ReleaseKinetics ofVancomycin andTigecycline fromPEG-
PPS Coatings. )e titanium pins were visually examined to
be red on the surface, confirming application of antibiotic
coating with use of rhodamine (Figure 1). SEM was used to
evaluate the microstructure of the polymer and demon-
strated 97% coverage with a smooth polymer surface and
coating thickness on the micron scale (Figure 1). Pins were
submerged in PBS, and the in vitro release of vancomycin
BioMed Research International 3
and tigecycline was determined using HPLC, demonstrating
the same burst pattern as previously described [19].
3.2. Effect of Antibiotic Coatings on In Vivo Bioluminescent
Signals. Bacterial burden, as measured by bioluminescence
signaling, peaked on day 7 (5.7×106± 7.4×106 photons/s/
cm2/sr) in the mice treated with PEG-PPS alone and
remained above 2.4× 5 photons/s/cm2/sr throughout the 42-
day experiment, indicating a chronic infection (Figures 2(a)
and 2(b)). Vancomycin coatings resulted in a statistically
significant reduction in bioluminescence signals on days 14,
28, and 42 (25-, 9-, and 4-fold, respectively, p< 0.01).
Tigecycline coatings also resulted in a statistically significant
reduction in bioluminescence signals on days 14, 28, and 42
(19-, 8-, and 4-fold, respectively, p< 0.01) compared with
PEG-PPS alone. )ere was no difference in bacterial burden
between vancomycin and tigecycline treatment groups
throughout the 42-day study period.
3.3. Effect of Antibiotic Coatings on Ex Vivo Bacterial Counts.
Implants and surrounding soft tissue and bone from the
fracture site were harvested at the completion of the
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Figure 1: (a) )e structure of PEG-PPS polymer used to coat metal implants. (b) )e visualization of the polymer coating is demonstrated
by a model molecule, rhodamine, which was dispersed in the PEG-PPS coating solution prior to coating (− , bare titanium pin; +3(w/v)%
PEG-PPS-coated pin containing rhodamine; ++, 6(w/v) % PEG-PPS-coated pin containing rhodamine). (c) Scanning electron microscopic
(SEM) images of the surfaces of a bare titanium pin, a titanium pin-coated with PEG-PPS containing vancomycin, and a titanium pin-coated
with PEG-PPS containing tigecycline. (d) In vitro release of vancomycin from 3 to 6 (w/v)% of PEG-PPS-coated titaniumK-wires in 150 μl of
PBS at 37°C. (e) Daily release vancomycin per pin quantified via HPLC (N� 3, mean± SEM). (f ) A higher magnification of the surface
morphology and the X-ray microanalysis of available elements on the surface of a PEG-PPS-coated titanium pin.
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experiment (POD 42) and ex vivo CFUs determined
(Figures 3(a) and 3(b)). Mice implanted with PEG-PPS
alone had 3.7 ± 1.1× 105 CFUs isolated from the peri-im-
plant tissue and 2.8± 1.5 ×102 CFUs isolated from the
implants. Vancomycin- and tigecycline-coated pins both
resulted in a significant reduction in bacterial CFUs after
the 42-day experiment. Vancomycin-coated pins grew out
a mean of 2 ± 2 CFUs (139-fold reduction) and zero CFUs
in the peri-implant tissue. Tigecycline-coated pins resulted
in a mean of 1.8± 1.8 ×101 CFUs from the implants (15-
fold reduction) and 6.3± 4.5 ×101 CFUs isolated from the
peri-implant tissue (5991-fold reduction). )e homoge-
nized samples were then cultured for an additional 48
hours to confirm the presence or absence of bacteria.
Vancomycin coatings resulted in bacteria present in 1 of 5
implant cultures and 1 of 5 peri-implant tissue cultures.)e
tigecycline group had bacteria present in 2 of 5 of the ex
vivo peri-implant tissue cultures and 1 of 5 of the ex vivo
implant cultures.
3.4. Effect of Antibiotic Coatings on X-Ray Imaging. Mice
treated with PEG-PPS alone, via qualitative analysis, dis-
played more radiographic findings consistent with osteol-
ysis, bony destruction, involucrum, and implant loosening,
when compared to mice treated with vancomycin or tige-
cycline (Figure 4). )e high-resolution X-rays demonstrated
qualitatively that both vancomycin and tigecycline coatings
prevent radiologic changes observed in the setting of implant
infection and osteomyelitis.
4. Discussion
)e most important finding of the present study is that
antibiotic coatings can be used to prevent implant infection
and osteomyelitis in an open fracture setting. Open fractures
have a higher incidence of infection, nonunion, and adverse
outcomes and generally lead to decreased patient satisfaction
and increased healthcare costs [6]. Decreasing the rate of
infection could increase the likelihood of fracture healing and
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Figure 2: (a) In vivo bioluminescence images of a representative mouse from each group over the study period. (b) Mean in vivo
bioluminescence signals throughout the study period.
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Figure 3: (a) CFU harvested from the joint tissue (log scale). (b) CFU harvested from the implants (log scale).
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improve outcomes. Preclinical data have demonstrated effi-
cacy of tigecycline against S. aureus in rabbit and rat models of
osteomyelitis [29, 30]. )us, we compared tigecycline to
vancomycin in a novel antibiotic coating applied to an
intramedullary implant in an open fracture model. To our
knowledge, this is the first open fracture model in mice using
intramedullary implants, and this model allows us to evaluate
potential therapeutic interventions for open fractures in a
short time period and obtain multiple endpoints in a single
mouse. Several key findings are presented in this study. First,
we demonstrated that vancomycin and tigecycline can be
encapsulated in a PEG-PPS polymer covalently linked to
implants and released for more than 7 days to maintain
therapeutic levels during the perioperative period. Second,
local release of vancomycin and tigecycline from the PEG-PPS
coatings resulted in significant reductions in bacterial burden
on the implant surface as well as in the surrounding bone and
soft tissue. )ird, bacteria were only present on one in five
implants coated with vancomycin and one in five implants
coated with tigecycline, as compared to all five in uncoated
and polymer-coated alone groups. Finally, the addition of
vancomycin or tigecycline to the coatings prevented bony
changes seen on X-ray in the setting of chronic implant
infection and osteomyelitis. Prior studies evaluating the ef-
ficacy of local antibiotics have focused on vancomycin-,
gentamicin-, or tobramycin-loaded cement beads [16, 17, 31].
)ese studies found a significant decrease in infection rates
when local antibiotics were used in addition to the standard of
care (washout, debridement, and at least 24 hours of in-
travenous antibiotics) [16, 17, 31]. More recent animal studies
have evaluated bioabsorbable antibiotic elution vehicles such
as demineralized bonematrix, calcium sulfate, and fibrin clots
[32, 33]. One such study in goats found tobramycin-im-
pregnated calcium sulfate pellets were effective at preventing
S. aureus infection in an infected proximal tibial defect [32].
Our coating is unique because it has an inner layer of polymer
covalently linked to the implant, which makes it resistant to
wear and shear forces during implantation, and an outer
polymer layer which has an active release of antibiotics driven
by reactive oxygen species (induced by neutrophil influx
during infection) and a passive release that maintains anti-
biotic levels above the MIC for one week after surgery (in the
vancomycin group). )ese properties protect the implant
from biofilm formation and enable the delivery of antibiotics
within the medullary canal as well as the surrounding soft
tissues. Preventing biofilm formation is critically important
because once a biofilm is formed, it is nearly impossible to
clear the infection without removing the implant. Current
methods of antibiotic delivery (antibiotic cement and bio-
degradable antibiotic beads) “clean the neighborhood” but do
not protect the surface of the implant. In our study, 8 of 10
antibiotic-coated implants were protected from bacterial
biofilm formation based on 48-hour culture in broth on a
shaking incubator.
Another specific advantage of a polymer coating on
intramedullary implants such as a tibial nail for an open tibia
fracture as opposed to using a cement-coated implant is that
the polymer coating maximizes the intramedullary nail
diameter. Antibiotic cement can be used to coat intra-
medullary nails; however, the nail diameter must be
downsized in order to accommodate the added cross-sec-
tional area that a cement coating creates [18].
Although cement-coated intramedullary nails can
improve infection rates, smaller diameter nails have a
higher rate of failure and can delay progression of weight
bearing [18]. )erefore, a low-profile polymeric coating
could enable surgeons to use a larger diameter nail, po-
tentially allowing earlier weight bearing and resulting in
lower failure rates. In addition, our polymer coating can be
applied to plates and screws, expanding the reach of this
technology beyond the current scope using antibiotic ce-
ment and biodegradable beads.
In our study, delivery of local vancomycin and tigecy-
cline preserved bone architecture and enabled fracture
PEG
Tigecycline
Vancomycin
Day 1 Day 21 Day 42
Figure 4: Representative radiograph from a mouse in each group over the study period.
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healing as observed on X-ray. One limitation of our study is
that we did not look more extensively at other endpoints of
fracture healing, such as micro-CT or histology. Although
fracture union is an important endpoint and necessary to
translate these findings into clinical practice, it is beyond the
scope of this study since we are presenting proof of concept
for a novel open fracture model and implant coating with
controlled release of antibiotics. To further demonstrate
efficacy of this coating, we will assess the impact of the
antibiotic coating on new bone formation, bone remodeling,
and osseointegration as determined through manual testing,
histology, and micro-CT.
Elution of antibiotics from PMMA beads has been
shown to result in high local concentrations in the bone and
soft tissue, while limiting serum concentrations [33]. )is
allows for maximal local effect, while minimizing systemic
toxicity. Although we did not specifically measure serum
concentrations in this study, it can be assumed that local
release of antibiotics in our study results in similar systemic
uptake as previously described [34]. A high local concen-
tration and low serum concentration is especially important
for tigecycline, which commonly causes nausea and vom-
iting (seen in 1 of 4 patients) when used intravenously.)ese
side effects are dose dependent. )erefore, local release of
tigecycline could be used to effectively treat open fractures or
chronic infection while limiting side effects [35, 36]. In-
terestingly, the concentration of tigecycline released from
the polymer coatings in this study was below the MIC for
Xen36 S. aureus but was effective in eliminating bacteria in 3
of 5 mice. )is may be due to the large initial burst of
tigecycline on day 1 or theoretically because local antibiotic
therapy requires lower concentrations of drug to achieve an
antimicrobial effect.
As previously mentioned, we were unable to completely
eliminate infection in our study, as 1 mouse in the vanco-
mycin group and 2 in the tigecycline group had bacteria
present on the implant or in the peri-implant tissue after the
42-day experiment. One explanation for this is that we used
local antibiotic therapy alone without the addition of in-
travenous antibiotics or surgical washout, which is the
standard of care for open fractures. We plan to assess the
efficacy of combining intravenous antibiotics with antibiotic
coatings in future studies. Another approach is to optimize
the coating by incorporating a synergistic drug such as ri-
fampin, which has enhanced antibiofilm activity and ther-
apeutic benefit in cases of retained hardware [37–45].
In conclusion, the open fracture mouse model presented
in this study demonstrated a therapeutic benefit of vanco-
mycin- and tigecycline-coated implants against a local S.
aureus infection. )is study provides important preclinical
evidence in support of a novel antibiotic coating to prevent
biofilm formation and release antibiotics into bone and soft
tissue to decrease infection associated with open fractures. In
particular, this coating allows for one-stage fracture fixation
without the need for a second surgery to remove the anti-
biotic delivery vehicle (i.e., cement beads), which has the
potential to improve clinical outcomes. Taken together, our
findings suggest that this open fracture mouse model could
serve as a valuable preclinical in vivo model to evaluate and
optimize the treatment of open fractures prior to further
studies in humans.
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